Biomarkers for Human Heart Failure
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Mayo Clinic
- Enrollment
- 535
- Locations
- 1
- Primary Endpoint
- uAGT levels in high-risk chronic HF patients
Study Overview
Brief Summary
The purpose of this study is to establish the various ranges of proteins that can be assayed in the plasma and urine from hospitalized patients with all classes of heart failure and/or STEMI (ST-segment elevation myocardial infarction)/NSTEMI (Non-ST-segment elevation myocardial infarction), as well as history reviews.
Detailed Description
Schematic Design of the Study: Single blood draw, one random urine and 24-hr urine collection from hospitalized patients with chronic/acute heart failure and/or STEMI-NSTEMI. If there should be a subsequent hospitalization,another collection of a 45 ml blood sample, random urine and one 24-hour urine collection may be completed if indicated at initial hospitalization.
Aims:
The purpose of this study is to attempt to establish the various ranges of proteins that can be assayed from the plasma and urine of patients with all classes of heart failure and MI (myocardial infarction). Follow-up hospitalizations may result in another 45 ml blood draw, random urine and 24-hr. urine collection to evaluate the outcome of the heart failure treatment used with the previous hospitalization, if indicated in consent. A history review will be necessary as well.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosis of Acute decompensated heart failure
Exclusion Criteria
- •Hemoglobin less than 10, active cancer, or amyloidosis Patient with dialysis
Outcomes
Primary Outcomes
uAGT levels in high-risk chronic HF patients
Time Frame: 10 years
This study will provide new knowledge of the pathology and outcomes predicted by the use of uAGT in symptomatic chronic HF patients at high risk for future hospitalization and death.
Natriuretic peptide levels in ADHF patients
Time Frame: 20 years
new knowledge of pathology and outcomes in ADHF patients
Secondary Outcomes
No secondary outcomes reported
Investigators
John C Burnett
Principal Investigator
Mayo Clinic